Erik Kinnman
Vorstandsvorsitzender bei VIVESTO AB
Aktive Positionen von Erik Kinnman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| STAYBLE THERAPEUTICS AB | Direktor/Vorstandsmitglied | 01.01.2020 | - |
| ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL) | Direktor/Vorstandsmitglied | 01.01.2022 | - |
| Independent Dir/Board Member | 01.01.2022 | - | |
| VIVESTO AB | Vorstandsvorsitzender | 23.01.2023 | - |
| Kinnman Solutions AB | Vorsitzender | 01.01.2016 | - |
| Stayble AB | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Erik Kinnman
Ehemalige bekannte Positionen von Erik Kinnman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPRINT BIOSCIENCE AB | Vorstandsvorsitzender | 01.03.2021 | 01.01.2023 |
| Investor Relations Kontakt | - | 01.01.2023 | |
| ABLIVA AB | Vorstandsvorsitzender | 14.03.2016 | 03.02.2021 |
| Public Communications Contact | 14.03.2016 | 03.02.2021 | |
| INFANT BACTERIAL THERAPEUTICS AB | Technik-/Wissenschafts-/F&E-Leiter | 22.08.2014 | 01.01.2016 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01.01.2008 | 01.01.2011 |
| ░░░░░░░░░ ░░ | ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░ ░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Erik Kinnman
| Karolinska Institutet | Doctorate Degree |
| Stockholm School of Economics | Masters Business Admin |
Statistik
International
| Schweden | 15 |
Operativ
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Public Communications Contact | 2 |
Sektoral
| Health Technology | 9 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| ABLIVA AB | Health Technology |
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| SPRINT BIOSCIENCE AB | Health Technology |
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Danske Bank A/S (Sweden) | Finance |
| Stayble AB | |
ISR Immune System Regulation Holding AB
 ISR Immune System Regulation Holding AB Pharmaceuticals: MajorHealth Technology ISR Immune System Regulation Holding AB engages in pharmaceutical research for the treatment of viral diseases focusing on Human Immunodeficiency Virus (HIV). It is developing ISR048 for the novel treatment of HIV. The company was founded by Yen Lundgren and Ulf Ljungblad in September 17, 2015 and is headquartered in Solna, Sweden. | Health Technology |
| Kinnman Solutions AB |
- Börse
- Insiders
- Erik Kinnman
- Erfahrung
